medigraphic.com
ISSN 1995-9427 (Print)

2022, Number 1

<< Back Next >>

Invest Medicoquir 2022; 14 (1)

Clinical evolution of the functional capability in patients with systemic sclerosis treated with cyclophosphamide and reduce dose of steroids

Remedios BSE, Duran MK, Hernández MA, Grace RS, Fermín HE

Language: Spanish
References: 38
Page:
PDF size: 146.96 Kb.


ABSTRACT

Introduction. The systemic sclerosis is an autoimmune disease of the connective tissue where the vasculopathy happens initially and persist during all the disease. The functional capability (FC), the commitment of the system reveals muscleskeletic of the patient, than little lime or incapacities of temporary form or permanent the realization of certain shows, measurable with the instrument of evaluation. Methods. The questionnaire that was utilized is the Cochin Hand Function scale (CHFS), measure the degree of disability of the hands. The patients split into two groups according to the clinical stages obtained in previous published study. In the group A (clinical stages I and II) they included 16 patients and 15 patients (clinical stages III and IV) included B themselves in the group, (annex 2). Results. The applied medical treatment, previous validation, you improved the functional capability of the patients of both groups A and B, that is in clinical premature and overdue stages. Conclusions. Significant improvement in the functional capability of patients affected of systemic sclerosis, with the medical treatment applied, with clinical stability and humoral from initial stages of the disease was caught up with.


REFERENCES

  1. LeRoy, E. C, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988).

  2. Fériz AR, Louis MR, Espinoza RL, Khamashta M, Cerinic MM, Sanmartí R, et al. Enfermedades inflamatorias reumatológicas. Ed. Producciones científicas Ltda. PANLAR, 2016; cap.18. p.397-419.

  3. De Segovia A. Tratado Hispanoamericano de Reumatología: Vol. II. Bogotá: Ed. Printed Colombia Schering Plough. 2007; cap.11. p. 889-911.

  4. Acuña Aguilarte WF, Bautista Vargas MA, Cortes G, Hernández Torres L, Valdés Vega JL, Serra Valdés MA. Calcinosis cutis en el curso de síndrome de CREST. Rev Cuba Reumatol [Internet]. 2014 Abr [citado 2019 Abr. 30]; 16(1): 41-46. Disponible en: http://scieloprueba.sld.cu.

  5. Vera Lastra O, Sauceda Casas CA, Cruz Domínguez MP, Mendoza Álvarez SA, Sepulceda Delgado J. Esclerosis sistémica sin esclerodermia en pacientes mexicanos: Serie de casos. Reumatol Clin. [Internet]. 2018 [citada 2019 Abr 30]; 14(4): 230-232: Disponible en: http://www.reumatologiaclinica.org.

  6. Valentini G, Marcoccia A, Cuomo G, Ludici M, Vettori S. The concept of early systemic sclerosis following 2013 ACREULAR criteria for the classification of systemic sclerosis.[Internet]. 2014 [Citado 21 abril 2015]; 10(1):38-44. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/?term=valentini.

  7. Rodríguez Hernández JF, Iglesias Sánchez JL, Dueñas Miranda MC, Díaz Domínguez MA, Diez Cabrea M. Esclerosis Sistémica: Aspectos epidemiológicos clínicos en la provincia de Pinar del Rio. Rev. Cub. Reumatol [internet]. 2000 [Citada 2017 Marzo 23]; 2(1):19-26. Disponible en: http://www.revreumatologia.sld.cu.

  8. Remedios Batista SE, Montada Cedeño E, Rivas Carralero R. Caracterización clínica epidemiológica de pacientes con esclerosis sistémica en Holguín. Rev Cub de Reuma [Internet]. 2018 [citado 2019 Abr. 30]; 20(1). Disponible en: http://www.revreumatologia.sld.cu/.

  9. Reyes Llerena GA, Guibert Toledano ZM, López Cabreja G, Hernández Derivet C, et al. Esclerosis sistémica. Evaluación clínico-epidemiológica de una serie de casos en dos centros de referencia en Cuba [internet]. 2014 [Citada 2017 Marzo 23]; 6(1): [Aprox 12 p.]. Disponible en: http://www.revreumatologia.sld.cu.

  10. Remedios Batista SE, Montada Cedeño E, Del Campo Avilés E, Torres Pérez L, Fernández Portelles A, et. al. Mecanismos etiopatogénicos en la esclerosis sistémica. CCM [Internet]. 2016 [citado 2016 Junio 22]; 20(1): [aprox 11 p.] Disponible en: http://www.revcomed.sld.cu.

  11. García de la Peña Lefebvrea P. Aspectos clínicos novedosos en la esclerodermia. Rheumatol Clin [Internet]. 2008 [citado 22 mayo 2017]; 4(1):45-49. Disponible en: http://www.reumatologiaclinica.org.es.

  12. Ingegnoli F, Ughi N, Dinsdale G, Orenti A, Boracchi P, Allanore Y, Foeldvari I, Sulli A, Cutolo M, Smith V, Herrick AL. EULAR Study Group on Microcirculation in Rheumatic Diseases. Rheumatol [Internet]. 2017 [citado 2019 Abr 30] Nov; 37(11):1879-1890. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27469583/.

  13. Sociedad Argentina de Dermatología. Consenso sobre esclerodermia actualización [Internet]. 2015[citado 30 de abril 2019].Disponible en:http://www.sad.org.ar/wpcontent/uploads/2016/04/ConsensoEsclerodermia 16. Allanore Y, Simms R, Distler O, Maria Trojanowska M, Pope J, Christopher P, et al. Systemic sclerosis. Primer Macmillan Publisher Limited [Internet]. 2015 [Citado 30 Abril 2019]; 1: 1-21. Disponible en: http://go.nature.com/lchkcA.

  14. Bell Castillo J, George Carrión W, García Céspedes ME, Rodríguez López J, George Bell MJ. Esclerosis sistémica progresiva en una mujer joven. MEDISAN [Internet]. 2015 Mayo [citado 2019 Abr. 30]; 19(5): 628-637. Disponible en: http://scielo.sld.cu.

  15. Consejo General de Colegios Oficiales de Farmacéuticos. Esclerosis Sistémica (Esclerodermia). España: Ed CGCOF. 2017 [Internet]. [citado 2020 Abr. 30]; 10(59):1-22.Disponible en: http://www.portalfarma.com

  16. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. [Internet]. 2003 [Citado 23 Jul. 2018]; 22(4): [aprox 1]. Disponible en: http://dx.doi.org/10.1007/s10067-003-0733-2.

  17. Masuii Y, Asano Y, Takahashi T, Shibata S, Akamata, et.al. Clinical significance of monitoring serum adiponectin levels during intravenous pulse CYC therapy in interstitial lung disease associated with systemic sclerosis. Mod Rheumatology [Internet]. 2013 [Citado 25 Abril 2019]; 23(2): [aprox1].Disponible en: http://www.ncbi.nln.nih.gov/pubmed?

  18. Tochimoto A, Kawaguchi Y, Hara M, Tateishi M, Fukasawa C, Takagi K, et al. Efficacy and safety of intravenous ciclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatic [Internet]. 2011 [Citado 25 abril 2019]; 21(3):296-301. Disponible en: http://www.ncbi.nln.nih.gov/pubmed?

  19. Schulz SW, O' Brien M, Maqsood M, Sandorfi N, Del Galdo F, Jimenez SA. Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide. J. Rheumatol [Internet]. 2009 [Citado 2018 Abril 25]; 36(8):1653-6. Disponible en: http://www.ncbi.nln.nih.gov/pubmed?

  20. Pérez Campos D, Estévez Del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Rheumatol. Clin [Internet]. 2012 [Citado 23 Mar 2018]; 8(2):58-62. Disponible en: http://www.elsevier.es/en/linksolver/pdf/pii/s1699-.

  21. Elhai M, Meunier M, Matucci- Cerinic M, EUSTAR (EULAR Scleroderma Trials and Research Group), et al. Outcome of patients with Systemic Sclerosis associated polyarthritis and myopathy treated with tociluzimab or abatacept: a EUSTAR observational study .Ann. Rheum. Dis [Internet]. 2013 [Citado 23 Mar 2018]; 72(7):1217-20. Disponible en: http: //www.ncbi.nlm.nih.gov/pubmed.

  22. Jordan S, Distler JH, Maurer B. EUSTAR Rituximab study group, et al. Effects and safety of rituximab in Systemic Sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group Ann. Rheum Dis [Internet]. 2015 [Citado 23 Mar 2018]; 74 (6):1188-94.Disponible en: http: //www.ncbi.nlm.nih.gov/pubmed.

  23. Abraham S, Steen V. Optimal management of digital ulcers in Systemic Sclerosis. There Clin Risk Manag. [Internet]. 2015 [citada 2019 sept 12]; 11: 939 -947: Disponible en: http://www.ncbi.nlm.nih.gov/pubmed?

  24. Martin Hertl, MD, PhD, Manuales MSD [Internet]. Ed. Rush University Medical Center; dic. 2018. Trasplante de células madre. Manuales MSD Última revisión completa; [Citado 25 Mayo 2020]; [Aprox 18p.].Disponible en: https://www.msdmanuals.com/es/hogar/trastornosinmunol%C3%B3gicos/trasplante/trasplante-de-c%C3%A9lulas-madre.

  25. Del Papa N, Pignataro F, Zaccara C, Maglioni W, Minniti A. Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis Front. Immunol [Internet]. France 16 Oct 2018 [Citado 25 Mayo 2020]; 9:2390. Disponible en:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198074/.

  26. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomized phase 2 trial. Lancet. [Internet]. 2011[Citado 25 May 2019]; 378(9790):498-506. Disponible en: http://www.ncbi.nln.nihgov/ PubMed? term =burt.

  27. Milanetti F, Bucha J, Testori A, Burt RK. Division of Immunotherapy, Northwestern University Feinberg School of Medicine. Autologous hematopoietic stem cell transplantation for systemic sclerosis. Chicago, USA. Arthritis Rheum [Internet]. 2011 [Citado 25 May 2019]; 12(1):16-28. D isponible en: http://www.ncbi.nln. Nihgov / PubMed?

  28. Richard A. Nash, Peter A. Sweeney Mc, Daniel E. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood [Internet]. 2017 August [Citado 25 Abril 2019]; 110 (4):1388-1396: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmc 1939909/figure/f5/? report= objectonly.

  29. ABC ENFFERMEDADES. El trasplante autólogo de células madre hematopoyéticas ofrece mayores beneficios a largo plazo que el tratamiento con inmunosupresores en la esclerodermia grave [Internet]. Madrid: Enfermedades Autoinmunes; 2018 [Citado 25 Marzo 2020]. Disponible en: https://www.abc.es/espana/madrid/#vca=menu&vmc=abces&vso=noticia.foto.salud&vli=salud.enfermedades.

  30. Keith M. Sullivan, Ellen A. Goldmuntz, Lynette Keyes-Elstein, et al. Trasplante autólogo de células madre por mieloablacion, en esclerodermia grave. N Engl J Med [Internet]. 2018 [Citado 25 Abril 2020]; 378:35-47. Disponible en: https://www.fundaciontorax.org.ar/page/index.php/pacientes.

  31. Femke C van Rhijn-Brouwer, Julia Spierings, Anna van Rhenen, Jürgen Kuball, Jacob M van Laar. Second autologous haematopoietic stem cell transplantation in systemic sclerosis: a case report. Rheumatology [Internet]. July 2019 [Citado 25 Mayo 2020]; 58 (7), Pages 1305-1307. Disponible en: https://academic.oup.com/rheumatology/article/58/7/1305/5312897

  32. Shouval R, Furie N, Raanani P, Nagler A, Gafter-Gvili A. Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis [Internet]. 2018 [Citado 25 Mayo 2020] Disponible en: PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25058083

  33. Walker KM, Pope J; participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG).Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A Consensus of Systemic Sclerosis Experts Semin Arthritis Rheumn [Internet]. 2012 [Citado 23 Mar 2018]. Disponible en: http://linkinghub.elsevier.com/retrieve/pii/.

  34. Jhonson KL, Nelson JL, Furst DE, Mcsweeney PA, Roberts DJ, et al. Fell cell microchimerism in tissue from multiple sites in women with systemic sclerosis. Arthritis Rheum [Internet]. 2001 [Citado 25 Abril 2019]; 44(8):p.1848-54.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid.

  35. Chakravarty E. Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical? Arthritis Res There [Internet]. 2012 [Citado 25 Abril 2019]; 14(1):102. Disponible en: http://arthritis-research.com/content/14/1/102.

  36. López Mantecón AM, Hernández Cuellar MI, Prada Hernández D, Molinero Rodríguez C, Reyes Pineda Y. Esclerosis sistémica y embarazo. Rev. Cub. Reumatol [Internet]. 2015 [Citado 23 febrero 2016]; 15(2) p. [Aprox 1]. Disponible en: http://www.revreumatologia.sld.cu/.

  37. Cutolo M, Smith V, Furst DE, Khanna D, Herrick AL. Points to consider-Raynaud's phenomenon in systemic sclerosis. Rheumatology [Internet]. 2017 sep. 1 [Citado 2019 Abr. 30]; 56 (suppl_5): p 45-48. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/27469583/.

  38. Souza José do Rosário E, Cristiane Kayser. Nailfold capillaroscopy: relevance to the practice of rheumatology. Rev bras Reumatol [Internet]. 2015 [citado 2019 Abr. 30]; 5 5(3):264–271. Disponible en: http://www.reumatologia.com.br.




2020     |     www.medigraphic.com